Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Investors Presenting at RESI San Diego

2 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is gearing up for the highly anticipated RESI San Diego conference, bringing together investors, strategic partners, and early-stage life science innovators for a full day of insightful discussions and high-value networking during Convention Week.

This year’s panel lineup will explore some of the most important trends shaping early-stage healthcare investment and partnering, spanning pharma, medtech, diagnostics, oncology, AI, and venture financing. Attendees can expect perspectives from venture capital firms, corporate venture groups, pharmaceutical companies, strategics, and experienced healthcare investors actively evaluating emerging opportunities across the life science landscape.

As a global partnering conference focused on connecting early-stage companies with investors and strategic partners, RESI San Diego is designed to foster meaningful conversations between fundraising CEOs and active dealmakers. The panels will provide tactical insight into how investors assess opportunities, what strategic partners are looking for, and how companies can position themselves in today’s increasingly competitive fundraising environment.

Join the panelists below at RESI San Diego:

Friedemann-Janus
Friedemann Janus
Bayer		 Shiv-Krishnan
Shiv Krishnan
Daiichi Sankyo Co., Ltd.		 Eva-Dahlen
Eva Dahlén
Novo Nordisk
Yaron-Daniely
Yaron Daniely
aMoon Fund		 Claudia-Generaux
Claudia Generaux
Bristol Myers Squibb		 Lana Ghanem
Lana Ghanem
Hikma Ventures
Kit-Law
Mankit Law
GlaxoSmithKline (GSK)		 Debbie-Lin
Debbie Lin
T.Rx Capital		 Priya-Balachandran
Priya Balachandran
Life Science Angels
Andrew-Strong
Andrew Strong
Cancer Focus Fund		 Randy-Berholtz
Randy Berholtz
Mesa Verde Venture Partners		 Gunes-Bozkurt
Gunes Bozkurt
Beiersdorf
Damian-Carvajal-Ibanez
Damian Carvajal Ibanez
Debiopharm		 Nicolas-Cindric
Nicolas Cindric
Yahara Ventures		 Han-Dai
Han Dai
Viva BioInnovator
Luca-Giani
Luca Giani
Alumni Ventures		 Sam-Gussman-Toh
Sam Gussman-Toh
ARPA-H		 Ole-Henrik-Bang-Andreasen
Ole Henrik Bang Andreasen
Avant Bio
Rohit-Jain
Rohit Jain
HBS Alumni Angels of Northern California		 Ray-Jordan
Ray Jordan
Elmstead Holdings		 Mohsin-Khan
Mohsin Khan
Fortress Biotech
Cheryl-Kuai
Cheryl Kuai
Sixty Degree Capital		 Don-Lin
Don Lin
Guoqian Venture Capital Investment		 Andrew-Merken
Andrew Merken
Polsinelli PC
Ralph-Morales
Ralph Morales III
Aquillius Ventures		 Nick-Mourlas
Nick Mourlas
ReefHaven Ventures		 Mahesh-Narayanan
Mahesh Narayanan
Neuvation Ventures
Stephanie-Oestreich
Stephanie Oestreich
Myeloma Investment Fund		 Soyoung-Park
Soyoung Park
1004 Venture Partners		 Preetha-Ram
Preetha Ram
Pier 70 Ventures
Bob-Sweeney
Bob Sweeney
Global Health Impact Fund		 Divya-Yerraguntla
Divya Yerraguntla
Life Science Angels		 Chris-Yoo
Chris Yoo
Xcellerant Ventures
Register for RESI San Diego

Tags: , , , , , , , , , , , , ,

RESI Innovator’s Pitch Challenge Winner Amets Biotechnology on Advancing Gene Therapies for Rare Diseases 

2 Jun

By Caitlin Dolegowski, Program Director, LSN

In this interview, Nicholas Weber of Amets Biotechnology discusses the company’s work advancing gene therapies for rare pediatric diseases, including PFIC2, and shares insight into the future of rare disease innovation. Amets Biotechnology was recognized at RESI Europe as an Innovator’s Pitch Challenge winner for its promising next-generation gene therapy approach. 

Apply to Pitch at RESI Boston

 

Tags: , , , ,

What Investors Need to Hear: Turning Your Pitch into Investor Signal 

2 Jun

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

When pitching to investors, companies often focus on the science and the benefit to the patient. While of course important, they are missing crucial information investors need to make a decision on whether or not to move forward. Investors are busy – the quicker they can make a decision, the better – there is no guarantee they will have the time to look further into a company after a pitch, so companies should make the best use of their attention while they have it.

How do investors make their decisions? What questions do they ask? LSN will be running a 3 webinar series that cover how investors make their decisions, how to cover that information clearly in your pitch, and how to translate that into positive signal from investors. Register for these webinars below:

June 4 | 1:00 PM ET
De-Risking, Shaping, and Micro-Investment – Sign Up

Strong science alone is rarely enough to secure funding. Rick Berenson (Anchor Node project) explores how investors evaluate early-stage risk and how to transform a scientific story into a shaped, investable asset. Learn how micro-investment acts as an early filtering mechanism, how to sequence de-risking activities, and how to rigorously prepare for investor outreach ahead of RESI San Diego.

June 11 | 1:00 PM ET
From Pitch Deck to De-Risk Deck – Sign Up

Investors look for legibility and risk reduction, not just vision. Dennis Ford (Founder & CEO, Life Science Nation) explains why traditional pitch decks fail and introduces the “de-risk deck”—a framework centered on structured evidence and strategic capital formation. Gain critical insights into investor targeting, outreach strategy, and the realities of life science fundraising timelines before RESI San Diego.

June 18 | 1:00 PM ET
Science to Signal – Sign Up

Max Braht and Karen Deyo introduce the *Science to Signal* framework, designed to help startups translate scientific merit into clear investment signals. Learn how this system aligns development strategy with risk assessment, its enterprise implementation in incubators, and join Dennis Ford (CEO, Life Science Nation) for a closing Q&A on fundraising strategy ahead of RESI San Diego.

Register for RESI San Diego

Tags: , , , , , , ,

INNOPOLIS Jeonbuk, Title Sponsor of RESI San Diego 2026, to Host Jeonbuk Advanced Bio Boost-Up Innovation Showcase

27 May

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to announce the INNOPOLIS Jeonbuk as a Title Sponsor of RESI San Diego 2026.

As part of the Jeonbuk Advanced Bio Boost-Up Platform initiative, INNOPOLIS Jeonbuk will host the Jeonbuk Advanced Bio Boost-Up Innovation Showcase at RESI San Diego on Monday, June 22, 10:00am – 12:00pm, featuring innovative life science companies from South Korea. The showcase aims to highlight emerging Korean biotech and healthcare technologies while connecting participating companies with global investors, strategic partners, and commercialization opportunities.

The Jeonbuk Advanced Bio Boost-Up Platform initiative is supported by the Ministry of Science and ICT of Korea and the Korea Innovation Foundation (INNOPOLIS Foundation), with the goal of strengthening Jeonbuk’s position as a global bio innovation hub. Through this initiative, regional startups and emerging companies are being supported in their efforts to expand internationally and engage with the global life science ecosystem.

South Korea has rapidly emerged as one of Asia’s leading biotechnology and healthcare markets, supported by strong scientific talent, advanced manufacturing capabilities, and increasing government investment in innovation. Within this landscape, Jeonbuk is actively developing its bio industry through strategic support for therapeutics, medical devices, digital health, diagnostics, regenerative medicine, and advanced biomanufacturing.

Participating companies include:

WittGen Biotechnologies – developer of a GenAI-based single-cell multi-omics simulation platform focused on oncology, immunology, and rare diseases.

 

Cellebrain – advancing MSC-based gene delivery technologies for oncology, fibrosis, and rare disease applications.

 

Youth Bio Global – developing allogeneic ECFC-based regenerative cell therapy platforms targeting vascular regeneration and ischemic diseases.

 

Erudio Bio Korea – developer of semiconductor-based multiplex diagnostic and AI molecular analysis technologies for preventive screening and oncology applications.

 

BASGENBIO Co., Ltd. – an AI-driven drug discovery company focused on target discovery and preclinical decision-support technologies.

 

VIEL-T Co., Ltd. – developing programmable RNA therapeutics platforms for next-generation precision medicine applications.

In connection with the initiative, INNOPOLIS Jeonbuk recently hosted the Global Investment Attraction Strategy & IR Capability Enhancement Seminar on May 21, 2026, at the Jeonbuk Techno Business Center in South Korea. The seminar brought together regional biotech companies, ecosystem stakeholders, and industry experts to discuss global fundraising strategies, investor engagement, and international commercialization opportunities for Korean life science companies.

As part of the program, Life Science Nation (LSN) shared insights on:

  • Global fundraising and investor outreach strategies
  • Building effective IR and partnering pipelines
  • Preparing Korean startups for international investors and markets
  • Opportunities through RESI and the global LSN ecosystem

The event also included the signing of a Memorandum of Understanding (MOU) between LSN and BSR Korea to strengthen collaboration in supporting Korean biotech and healthcare companies seeking global expansion and cross-border partnership opportunities.

Through the showcase at RESI San Diego 2026, INNOPOLIS Jeonbuk seeks to strengthen cross-border collaboration and provide Korean startups with greater access to global capital and partnering opportunities.

The program will feature:

  • An introduction to the Jeonbuk bio ecosystem and the Jeonbuk Advanced Bio Boost-Up Platform initiative
  • Startup pitches from participating Korean life science companies
  • Investor and industry expert feedback sessions
  • Networking opportunities with global investors and strategic partners

RESI San Diego 2026 will take place on Monday, June 22, at the JULEP Venue in San Diego. Join us for a full day of one-on-one partnering meetings, engaging programming, and the opportunity to build meaningful connections within the global life sciences ecosystem.

About INNOPOLIS Jeonbuk

The INNOPOLIS Jeonbuk is part of Korea’s national innovation cluster network operated by the Korea Innovation Foundation under the Ministry of Science and ICT. Based in Jeonbuk Special Self-Governing Province, the cluster supports the commercialization and global expansion of innovative technologies and startups across the life sciences sector.

Through the Jeonbuk Advanced Bio Boost-Up Platform initiative, the cluster is focused on strengthening regional bio innovation capabilities and supporting Korean life science companies in accessing global investors, strategic partners, and international markets.

As a Title Sponsor of RESI San Diego 2026, the INNOPOLIS Jeonbuk aims to expand global collaboration opportunities for Korean startups and further connect the Korean bio ecosystem with the international life science community.

Register for RESI San Diego

Tags: , , , , , , , , , , , , ,

New Frontiers in Diagnostics: Investors Look Toward Earlier Detection and Smarter Disease Monitoring at RESI San Diego 

27 May

By Momo Yamamoto, Senior Investor Research Analyst, LSN

At RESI San Diego, the “New Frontiers in Diagnostics: Investing in Technologies Enabling Earlier Disease Detection” panel will bring together investors and industry leaders to explore one of the most rapidly evolving areas in healthcare innovation: diagnostics.

As advances in liquid biopsies, molecular diagnostics, AI-enabled imaging, and point-of-care technologies continue to reshape healthcare, diagnostics are increasingly moving beyond simple detection tools and becoming central to disease prevention, monitoring, and personalized treatment strategies. Earlier and more precise detection has the potential to improve patient outcomes, reduce healthcare costs, and create entirely new models of care delivery.

Meet the Panelists

Priya-Balachandran
Priya Balachandran
Life Science Angels
(Moderator)		 Randy-Berholtz
Randy Berholtz
Mesa Verde Venture Partners		 Yaron-Daniely
Yaron Daniely
aMoon Fund
Debbie-Lin
Debbie Lin
T.Rx Capital		 Soyoung-Park
Soyoung Park
1004 Venture Partners

The panel will examine where investors and strategic partners see the greatest opportunities emerging across the diagnostics landscape, particularly in oncology screening, cardiometabolic disease, and chronic disease monitoring. With healthcare systems placing greater emphasis on prevention and longitudinal patient management, diagnostic companies are facing growing demand—but also increasing pressure to demonstrate meaningful clinical and economic value.

For early-stage companies, the diagnostics space presents unique opportunities alongside complex commercialization challenges. Unlike many therapeutics companies, diagnostics startups must often navigate overlapping clinical validation, reimbursement, regulatory, and adoption hurdles simultaneously. Investors are increasingly looking for companies that can clearly demonstrate clinical utility, integrate effectively into provider workflows, and build compelling reimbursement strategies early in development.

Panelists are expected to discuss the milestones and study designs that help diagnostic companies stand out in a crowded and competitive market. Topics may include generating real-world evidence, designing validation studies that resonate with payers and providers, and establishing partnerships with laboratories, health systems, and pharmaceutical companies to accelerate adoption.

The rise of AI-enabled diagnostics is also expected to play a central role in the conversation. As machine learning tools become more integrated into imaging, pathology, and predictive analytics platforms, investors are paying close attention to how startups validate algorithms, manage regulatory considerations, and demonstrate measurable improvements in clinical decision-making.

Beyond the technology itself, the panel will likely explore broader market trends shaping investor interest in diagnostics. Healthcare systems worldwide continue shifting toward preventative care models, while aging populations and rising chronic disease burdens increase demand for scalable monitoring solutions. In this environment, diagnostics companies capable of delivering actionable insights earlier in the patient journey may be particularly well-positioned to attract strategic partnerships and investment.

For founders attending RESI San Diego, the session offers an opportunity to better understand how investors evaluate diagnostics opportunities in today’s market and what differentiates successful companies from the broader field. From regulatory and reimbursement strategy to commercialization planning and partnership development, the panel aims to provide practical insight into building investable diagnostic platforms in an increasingly competitive healthcare landscape.

The “New Frontiers in Diagnostics” panel is part of RESI San Diego’s broader programming focused on emerging healthcare technologies, investment trends, and strategies for early-stage companies navigating today’s life science funding environment.

Register for RESI San Diego

Tags: , , , , , , , , , , , , , , , ,

How to Identify Best-Fit Investors at Partnering Events 

27 May

By Sougato Das, President and COO, LSN

Sougato-DasPartnering conferences are a great place to meet investors, in-licensors and strategic partners. These events tend to be segmented in the following ways:

1) Focus: General, Licensing/BD or Investment

2) Modality: Biotech, Device/Diagnostics, Digital Health

3) Therapeutic area: General or Therapeutic area-specific

4) Stage: General or Early Stage

While it seems obvious, it is critical to align your events (and your limited time and budget) with your company objectives. In my experience at dozens of different partnering conference, I’ve found that each of the above are largely binary. For example, while a Licensing/BD conference will have some investors attending, you’ll have many more meetings with investors at a investment-focused meeting. And vice-versa. Additionally, an interesting pattern that I’ve noticed is when it comes to stage, a partnering event that has a general focus tends to skew late-stage (clinical or later, with lots of players looking for phase 3 or commercial assets). This leaves companies with preclinical or early clinical assets scrambling to identify and meet the relatively few investors who are interested in early-stage companies.

Since partnering conferences allow for a limited number of outgoing meeting requests that can be in the ‘requested’ state, it’s important for you to be able to identify the attending investors that are a good fit for your company. This is complicated by the fact that investors typically don’t do a stellar job populating their profile with information that makes their remit clear. While it may be tempting to use the filters provided by the partnering system to identify best-fit investors, this ONLY works if every investor profile is consistently populated. Why? Because blank values are not returned in filtered searches. What does that mean? That means that if you use the filters in the partnering system to look for those who invest in oncology, and there are some oncology investors who have not filled out their therapeutic area field in their profile, those investors will not be returned in the results. Some partnering conference providers, such as RESI, prevent this issue by having the staff populate the investor profiles on behalf of the investors, ensuring that all profiles are complete and searchable.

All that said, what do you need to look for to find the investors that fit your company best? The most important criteria (that you probably know already if you’ve done any investor outreach) is stage. “Too early” is a response that every pre-clinical and phase 1 company has heard a million times. At RESI it’s easy. You can filter accurately on stage. But at other conferences that depend on the investor to self-populate their profile, you’ll have to read the profile carefully and visit the website. If it doesn’t say explicitly, then look at the portfolio companies.

The next aspect is the assets under management and the check size range. This kind of information not only shows if the investor is appropriate for the amount you’re raising, but also shows if the investor is indeed an investor and not a financial consultancy or investment bank (in some conferences, such entities end up being classified as investors).

Next, and as alluded to above, is the therapeutic area focus. While many investors go across therapeutic areas, some focus on only one or a few.

Next is the modality. Of course if you’re a med tech investor you don’t want to target a biotech-only investor. Within biotech, there are some investors that only do advanced therapies and some who do everything except advanced therapies. Etc.

Next there is the geographic focus. Some investors target specific geographies.

Finally, there is the investor type or model. Not all investors are equity investors. Some are debt, some royalty, some are venture builders, some are CROs that provide services for equity, etc.

If you have access, looking up the investor in Life Science Nation’s investor database will return all the details you need with regard to the above. Other databases have information on investments a given investor made, which provides some insight. By ensuring the investor you send a meeting request to is actually suitable for your company, you’ll maximize your ROI and, with any luck, extend your cash runway.

Register for RESI San Diego

Tags: , , , , , , , , , , , , , , , , , , , , , ,

Innovator’s Pitch Challenge: Where Deals Start

19 May

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

At most conferences, startup pitch competitions are treated as side programming. Founders present a deck, judges select winners, applause follows, and the event moves on.

At RESI San Diego, the Innovator’s Pitch Challenge (IPC) is designed differently.

The IPC is not simply about winning a competition. It is designed to help early-stage life science companies generate investor attention, create business development momentum, and accelerate conversations that continue long after the presentation ends.

For many companies, that interaction becomes the most valuable part of the experience.

“The discussions also felt far more relationship-driven than transactional,” said Sian Farrell, CEO of StimOxyGen. “Conversations extended beyond the pitch itself and focused on clinical strategy, regulatory pathways, commercialization, and long-term value creation.”

Unlike standalone pitch competitions, the IPC is integrated directly into the larger RESI partnering ecosystem. Participating companies also receive partnering access, poster presentation visibility, and exposure throughout the conference environment, creating multiple opportunities for follow-up interaction.

“The combination of the presentation and the partnering platform made a significant difference,” said Bram de Moor, CEO of You2Yourself. “RESI brought us into direct contact with European and transatlantic life science investors who specifically seek early-stage diagnostic and biomarker companies — an audience difficult to reach through cold outreach.”

The IPC also introduces an interactive audience component through “RESI cash,” distributed to attendees during registration. Participants allocate their RESI cash to the companies they believe demonstrate the strongest potential, creating additional visibility and engagement throughout the event.

For founders navigating today’s capital environment, opportunities that combine exposure with concentrated investor access are increasingly valuable.

As fundraising conditions continue to demand stronger differentiation and clearer commercialization pathways, platforms that help companies sharpen messaging and generate high-quality investor interaction have become increasingly important.

At RESI, the IPC is intended to serve exactly that purpose.

Selected companies receive:

  • Two 5-day RESI registrations
  • A six-minute company presentation followed by seven minutes of investor Q&A
  • Poster presentation space
  • Full partnering access
  • Exposure to investors, strategic partners, and pharma business development teams throughout Convention Week

For many founders, the IPC becomes more than a presentation opportunity. It becomes the place where investor conversations begin, strategic relationships form, and fundraising momentum accelerates.

Applications for the Innovator’s Pitch Challenge at RESI San Diego are currently open, with limited presentation slots remaining.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , ,

← Older Entries